Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 39.00
Bid: 38.00
Ask: 40.00
Change: 5.00 (15.15%)
Spread: 2.00 (5.263%)
Open: 33.00
High: 38.00
Low: 34.50
Prev. Close: 33.00
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

7 Dec 2023 14:31

UK shareholder meetings calendar - next 7 days

Friday 8 December 
Amedeo Air Four Plus LtdAGM
Ashoka India Equity Investment Trust PLCAGM
Associated British Engineering PLCAGM
Associated British Foods PLCAGM
Corcel PLCGM re disposal of 41% interest in the Mambare nickel/cobalt project
Hargreaves Lansdown PLCAGM
URA Holdings PLCGM re closing the fundraise
Monday 11 December 
IamFire PLCAGM with vote on name change to WeCap PLC
Pharma C Investments PLCGM re allowing investments in fintech, AI sectors
SigmaRoc PLCGM re reverse takeover
Tribal Group PLCGM re cash offer by Tiger Bidco 1 Ltd
Vela Technologies PLCAGM
Tuesday 12 December 
Atalaya Mining PLCEGM re redomiciliation to Spain from Cyprus
Blackrock Greater Europe Investment Trust PLCAGM
Distil PLCGM re placing and subscription
Gelion PLCAGM
Wednesday 13 December 
Dechra Pharmaceuticals PLCAGM
Limitless Earth PLCAGM
Softcat PLCAGM
Volution Group PLCAGM
Thursday 14 December 
Aeorema Communications PLCAGM
CleanTech Lithium PLCGM re equity raise approval
Driver Group PLCFull Year Results
eEnergy Group PLCAGM
Ethernity Networks LtdGM re authority to allot shares on non-preemptive basis
Fintech Asia LtdAGM
Helium One Global LtdAGM
Marwyn Value Investors LtdAGM
Quarto Group IncGM re cancelling trading on London's Main Market
Sareum Holdings PLCAGM
  
Copyright 2023 Alliance News Ltd. All Rights Reserved. 

Read more
23 Nov 2023 14:28

IN BRIEF: Sareum Holdings draws down on equity prepayment facility

Sareum Holdings PLC - Cambridge, England-based pharmaceutical company, focused on developing kinase inhibitors to treat autoimmune diseases and cancer - Says that it has drawn down on the GBP300,000 second deposit in respect of a previously announced equity prepayment facility.

Read more
9 Nov 2023 13:47

EARNINGS AND TRADING: MetalNRG hails Gold Ridge findings

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
3 Nov 2023 13:59

Sareum secures Japan patent for kinase inhibitor asset

(Sharecast News) - Biotechnology firm Sareum announced on Friday that it has received a notice of allowance from the Japan Patent Office for a patent associated with SDC-1801, its primary TYK2/JAK1 kinase inhibitor.

Read more
3 Nov 2023 09:01

Sareum says patent notice in Japan boosts confidence in SDC-1801

(Alliance News) - Sareum Holdings PLC on Friday said it received a notice of allowance from Japan's Patent Office for a patent relating to its lead TYK2/JAK1 kinase inhibitor, SDC-1801.

Read more
9 Oct 2023 15:06

Sareum losses widen as clinical trials continue

(Sharecast News) - Biotechnology company Sareum Holdings reported a loss of £3.2m after tax in its final results on Monday, widening from last year's £2.2m due to heightened expenses from initiating clinical studies with SDC-1801, despite aligning with market anticipations.

Read more
9 Oct 2023 10:58

Sareum says earnings down but product development going well

(Alliance News) - Sareum Holdings PLC on Monday said its annual loss widened and its cash reserves are substantially reduced, but that development and testing of its medicinal products is progressing well.

Read more
6 Sep 2023 14:35

Director dealings: Blackbird, Sareum insiders pick up shares

(Sharecast News) - Blackbird found itself with a number of entries on the list of director buys on Wednesday, after a number of insiders and associates bought shares.

Read more
4 Sep 2023 09:18

Sareum begins dosing participants in phase 1a trial for SDC-1801

(Alliance News) - Sareum Holdings PLC on Monday said it has successfully started the multiple ascending dose part of its phase 1a clinical trial for its SDC-1801 drug, following approval from the safety review committee.

Read more
16 Aug 2023 13:13

Sareum flagship drug trial progressing well ahead of annual results

(Alliance News) - Sareum Holdings PLC on Wednesday said a clinical trial for its main therapeutic is continuing as planned, and it hopes to use a new prepayment facility to further enhance development.

Read more
3 Aug 2023 14:16

IN BRIEF: Sareum secures GBP5 million of funding from RiverFort Global

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Agrees terms on equity prepayment facility of up to GBP5 million with RiverFort Global Opportunities PCC Ltd, as arranged by RiverFort Global Capital Ltd, with an initial deposit of GBP2 million. This is expected on August 4, net of associated costs.

Read more
26 Jun 2023 17:33

TRADING UPDATES: New patents for Sareum; Guanajuato hails assessment

(Alliance News) - The following is a round-up of updates by London-listed companies, issued Monday and not separately reported by Alliance News:

Read more
26 Jun 2023 10:54

Sareum granted new patents in China, US

(Sharecast News) - Clinical-stage biotechnology developer Sareum announced the granting of patents for its lead kinase inhibitors in China and the United States on Monday.

Read more
6 Jun 2023 13:36

IN BRIEF: Sareum doses first subjects in psoriasis drug trial

Sareum Holdings PLC - Cambridge-based biotechnology company developing kinase inhibitors for autoimmune diseases and cancers - Announces successful dosing of first test subjects in a randomised, placebo-controlled phase 1a clinical trial for lead programme SDC-1801. SDC-1801 is a dual TYK2/JAK1 kinase inhibitor and potential new therapeutic for various autoimmune diseases with an initial focus on psoriasis. The phase 1a trial will investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of SDC-1801 in healthy subjects, in single and multiple ascending oral dose studies. Dosing has started in a specialist clinical unit in Melbourne, Australia. Sareum expects full safety data to become available during the first half of 2024, after which a phase 1b clinical study will commence post-haste if the Phase 1a trial obtains satisfactory results.

Read more
18 May 2023 14:31

TRADING UPDATES: Nuformix says NXP002 shows anti-inflammatory effect

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.